Plasmalogens in biological systems: Their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis

Current Medicinal Chemistry

Volumn 16, Issue 16, 2009, Pages 2021-2041

  Lessig J ^a   Fuchs, Beate ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Chloro fatty aldehyde; Chromatography; Chronic diseases; Lysophospholipids; Mass spectrometry; NMR; Plasmalogens; Vinyl ether

Indexed keywords

CAROTENOID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROXYALDEHYDE; PLASMALOGEN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

AGING; ALZHEIMER DISEASE; ANALYTIC METHOD; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARBON NUCLEAR MAGNETIC RESONANCE; CHRONIC KIDNEY FAILURE; DISORDERS OF PEROXISOMAL FUNCTIONS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS FRAGMENTOGRAPHY; NONHUMAN; OXIDATIVE STRESS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; REPERFUSION; REVIEW; SPINAL CORD ISCHEMIA; THIN LAYER CHROMATOGRAPHY;

AGING; ANIMALS; CELL MEMBRANE; DISEASE; HUMANS; INFLAMMATION; OXIDATION-REDUCTION; PLASMALOGENS;

EID: 68449093834     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788682164     Document Type: Review

References (232)

1. Zemski Berry, K.A.; Murphy, R.C. Free radical oxidation of plasmalogen glycerophosphocholine containing esterified docosahexaenoic acid: structure determination by mass spectrometry. Antioxid. Redox. Signal., 2005, 7, 157-169.
2. Wientzek, M.; Man, R.Y.K.; Choy, P.C. Choline glycerophospholipid biosynthesis in the guinea pig heart. Biochem. Cell Biol., 1987, 65, 860-868.
3. Farooqui, A.A.; Horrocks, L.A. Plasmalogens: Workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist, 2001, 7, 232-245.
4. Brosche, T.; Platt, D. The biological significance of plasmalogens in defense against oxidative damage. Exp. Gerontol., 1998, 33, 363-369.
5. Yavin, R.A.; Gatt, S. Oxygen-dependent cleavage of the vinyl-ether linkage of plasmalogens. 2. Identification of the low-molecular weight active component and the reaction mechanism. Eur. J. Biochem., 1972, 25, 437-446.
6. Foglia, T.A.; Nungesser, E.; Marmer, W.N. Oxidation of 1-O-(alk-1-enyl)-2,3-di-O-acylglycerols: Models for plasmalogen oxidation. Lipids, 1988, 23, 430-434.
7. Morand, O.H.; Zoeller, R.A.; Raetz, C.R.H. Disappearance of plasmalogens from membranes of animal cells subjected to photosensitized oxidation. J. Biol. Chem., 1988, 263, 11597-11606.
8. Khaselev, N.; Murphy, R.C. Susceptibility of plasmenyl glycero-phosphoethanolamine lipids containing arachidonate to oxidative degradation. Free Radic. Biol. Med., 1999, 26, 275-284.
9. Murphy, R.C. Free-radical-induced oxidation of arachidonoyl plasmalogen phospholipids: Antioxidant mechanism and precursor pathway for bioactive eicosanoids. Chem. Res. Toxicol., 2001, 14, 463-472.
10. Felde R.; Spiteller G. Plasmalogen oxidation in human serum lipoproteins. Chem. Phys. Lipids, 1995, 76, 259-267.
11. Albert, C.J.; Crowley, J.R.; Hsu, F.F.; Thukkani, A.K.; Ford, D.A. Reactive chlorinating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens: Identification of 2-chlorohexadecanal. J. Biol. Chem., 2001, 276, 23733-23741.
12. Leßig, J.; Schiller, J.; Arnhold, J.; Fuchs, B. Hypochlorous acid-mediated generation of glycerophosphocholine from unsaturated plasmalogen glycerophosphocholine lipids. J. Lipid Res., 2007, 48, 1316-1324.
13. Thukkani, A.K.; McHowat, J.; Hsu, F.F.; Brennan, M.L.; Hazen, S.L.; Ford, D.A. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in humanatherosclerotic lesions. Circulation, 2003, 108, 3128-3133.
14. Khaselev, N.; Murphy, R.C. J. Structural characterization of oxidized phospholipid products derived from arachidonate-containing plasmenyl glycerophosphocholine. Lipid Res., 2000, 41, 564-572.
15. Reiss, D.; Beyer, K.; Engelmann, B. Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro. Biochem. J., 1997, 323, 807-814.
16. Gorgas, K.; Teigler, A.; Komljenovic, D., Just, W.W. The ether lipid-deficient mouse: Tracking down plasmalogen functions. Biochim. Biophys. Acta, 2006, 1763, 1511-1526.
17. Engelmann, B. Plasmalogens: Targets of oxidants and major lipophilic antioxidants. Biochem. Soc. Trans., 2004, 32, 147-150.
18. Hall, L.M.; Murphy, R.C. Analysis of stable oxidized molecular species of glycerophospholipids following treatment of red blood cell ghosts with t-butylhydroperoxide. Anal. Biochem., 1998, 258, 184-194.
19. Khaselev, N.; Murphy, R.C. Peroxidation of arachidonate containing plasmenyl glycerophosphocholine: Facile oxidation of esterified arachidonate at carbon-5. Free Radic. Biol. Med., 2000, 29, 620-632.
20. Loidl-Stahlhofen, A.; Hannemann, K.; Felde, R.; Spiteller, G. Epoxidation of plasmalogens: Source for long-chain alpha-hydroxyaldehydes in subcellular fractions of bovine liver. Biochem. J., 1995, 309, 807-812.
21. Loidl-Stahlhofen, A.; Hannemann, K.; Spiteller, G. Generation of alpha-hydroxyaldehydic compounds in the course of lipid peroidation. Biochim. Biophys. Acta, 1994, 1213, 140-148.
22. van den Bosch, H.; Schrakamp, G., Hardemann, D.; Zomer, A.W.; Wanders, R.J.; Schutgens, R.B. Ether lipid synthesis and ist deficiency in peroximal disorders. Biochimie, 1993, 75, 183-189
23. Lohner, K. Is the high prospensity of ethanolamine plasmalogens to form non-lamellar lipid structures manifested in the properties of biomembranes? Chem. Phys. Lipids, 1996, 81, 167-184.
24. Nagan, N.; Zoeller, R.A. Plasmalogens: Biosynthesis and functions. Prog. Lipid Res., 2001, 40, 199-229.
25. Lee, T.C. Biosynthesis and possible biological functions of plasmalogens. Biochim. Biophys. Acta, 1998, 1394, 129-145.
26. Maeba, R.; Ueta, N. Determination of choline and ethanolamine plasmalogens in human plasma by HPLC using radioactive triiodide (1-) ion (125I3-). Anal. Biochem., 2004, 331, 169-176
27. Yavin, E.; Brand, A.; Green, P. Docosahexaenoic acid abundance in the brain: A biodevice to combat oxidative stress. Nutr. Neurosci., 2002, 5, 149-157.
28. Evans, R.W.; Weaver, D.E.; Clegg, E.D. Diacyl, alkenyl, and alkyl ether phospholipids in ejaculated, in utero- and in vitro-incubated porcine spermatozoa. J. Lipid Res., 1980, 21, 223-228.
29. Flesch, F.M.; Gadella, B.M. Dynamics of the mammalian sperm plasma membrane in the process of fertilization. Biochim. Biophys. Acta,, 2000, 1469, 197-235.
30. Ladha, S. Lipid heterogeneity and membrane fluidity in a highly polarized cell, the mammalian spermatozoon. J Membr. Biol., 1998, 165, 1-10.
31. Martinez, P.; Morros, A. Membrane lipid dynamics during human sperm capacitation. Front. Biosci., 1996, 1, d103-117.
32. Borchman, D.; Byrdwell, W.C.; Yappert, M.C. Regional and age-dependent differences in the phospholipid composition of human lens membranes. Invest. Ophthalmol. Vis. Sci., 1994, 35, 3938-3942
33. Borchman, D.; Yappert, M.C.; Afzal, M. Lens lipids and maximum lifespan. Exp. Eye Res., 2004, 79, 761-768.
34. Estrada, R.; Borchman, D.; Reddan, J.; Hitt, A.; Yappert, M.C. In vitro and in situ tracking of choline-phospholipid biogenesis by MALDI TOF-MS. Anal. Chem., 2006, 78, 1174-1180
35. Huang, L.; Grami, V.; Marrero, Y.; Tang, D.; Yappert, M.C.; Rasi, V.; Borchman, D. Human lens phospholipid changes with age and cataract. Invest. Ophthalmol. Vis. Sci., 2005, 46, 1682-1689
36. 31P NMR spectroscopy. Comp. Biochem. Physiol. B Biochem. Mol. Biol., 2004, 137, 265-277.
37. Schiller, J.; Müller, K.; Süß, R.; Arnhold, J.; Gey, C.; Herrmann, A.; Leßig, J.; Arnold, K.; Müller, P. Analysis of the lipid composition of bull spermatozoa by MALDI-TOF mass spectrometry - a cautionary note. Chem. Phys. Lipids, 2003, 126, 85-94.
38. Hinkovska, V.T.; Dimitrov, G.P.; Koumanov, K.S. Phospholipid composition and phospholipid asymmetry of ram spermatozoa plasma membranes. Int. J. Biochem., 1986, 18, 1115-1121.
39. Fuchs, B.; Jakop, U.; Göritz, F.; Hermes, R.; Hildebrandt, T.; Schiller, J.; Müller, K. MALDI-TOF "fingerprint" phospholipid mass spectra allow the differentiation between ruminantia and feloideae spermatozoa. Theriogenology, 2009, 71, 568-575.
40. Jansen, G.A.; Wanders, R.J. Plasmalogens and oxidative stress: Evidence against a major role of plasmalogens in protection against superoxide anion radical. J. Inherit. Metab. Dis., 1997, 20, 85-94.
41. Diagne, A.; Fauvel, J.; Record, M.; Chap, H.; Douste-Blazy, L. Studies on ether lipids II. Comparative composition of various tissues from human, rat and guinea pig. Biochim. Biophys. Acta, 1984, 793, 221-231.
42. Naughton, J.A.; Trewhella, M.A. Positional distribution of acyl and alk-1-enyl groups in grey and white matter ethanolamine and choline phosphoglycerides of a marsupial, the koala. J. Neurochem., 1984, 42, 685-691.
43. Brosche, T.; Brueckmann, M.; Haase, K.K.; Sieber, C.; Bertsch, T. Decreased plasmalogen concentration as a surrogate marker of oxidative stress in patients presenting with acute coronary syndromes or supraventricular tachycardias. Clin. Chem. Lab. Med., 2007, 45, 689-691.
44. Zoeller, R.A.; Morand, O.H.; Raetz, C.H. A possible role for plasmalogens in protecting animal cells against photosensitized killing. J. Biol. Chem., 1988, 263, 11590-11596.
45. Brosche, T. Plasmalogen levels in serum from patients with impaired carbohydrate or lipid metabolism and in elderly subjects with normal metabolic values. Arch. Gerontol. Geriatr., 2001, 32, 283-294.
46. Messner, M.C.; Albert, C.J.; Hsu, F.-F.; Ford, D.A. Selective plasmenylcholine oxidation by hypochlorous acid: Formation of lysophosphatidylcholine chlorohydrins. Chem. Phys. Lipids, 2006, 144, 34-44.
47. Wanders, R.J.A.; Purvis, Y.R.; Heymans, H.S.A.; Bakkeren, J.A.J.M.; Parmentier, G.G.; van Eldere, J.; Eyssen, H.; van den Bosch, H.; Tager, J.M.; Schutgens, R.B.H. Age-related differences in plasmalogen content of erythrocytes from patients with the cerebro hepato-renal (Zellweger) syndrome: Implications for postnatal detection of the disease. J. Inherit. Metab. Dis., 1986, 9, 335-342.
48. Blank, M.L.; Wykle, R.L.; Snyder, F. The retention of arachidonic acid in ethanolamine plasmalogens of rat testes during essential fatty acid deficiency. Biochim. Biophys. Acta, 1973, 316, 28-34.
49. Ford, D.A.; Gross, R.W. Plasmenylethanolamineis the major storage depot for arachidonic acid in rabbit vascular smooth muscle and is rapidly hydrolyzed after angiotensin II stimulation. Proc. Natl. Acad. Sci. USA, 1989, 86, 3479-3483.
50. 2. A calcium-independent phospholipase with absolute f1-2 regiospecifity for diradyl glycerophospholipids. J. Biol. Chem., 1990, 265, 10622-1063.
51. 2 and its role in signal transduction. J. Lipid Mediat. Cell Signal., 1996, 14, 9-13.
52. 2 from bovine brain cytosol. J. Neurochem., 1992, 59, 708-714.
53. 2 and signal transduction. Brain Res. Brain Res. Rev., 1995, 21, 152-161.
54. Katsuki, H.; Okuda, S. Arachidonic acid as a neurotoxic and neurotrophic substance. Prog. Neurobiol., 1995, 46, 607-636
55. Williams, S.D.; Ford, D.A. Activation of myoardial cAMP-dependent protein kinase by lysoplasmenylcholine. FEBS Lett., 1997, 420, 33-38.
56. Sugiura, T.; Fukuda, T.; Masuzawa, Y.; Waku, K. Ether lysophospholipid-induced production of platelet-activating factor in human-polymorphonuclear leukocytes. Biochim. Biophys. Acta, 1990, 1047, 223-232.
57. Uemura, Y.; Lee, T.-C.; Snyder, F. A coenzyme A-independent transacylase is linked to the formation of platelet-activating factor (PAF) by generating the lyso-PAF intermediate in the remodeling pathway. J. Biol. Chem., 1991, 266, 8268-8272.
58. Nieto, M.L.; Venable, M.E.; Bauldry, S.A.; Greene, D.G.; Kennedy, M.; Bass, D.A.; Wykle, R.L. Evidence that hydrolysis of ethanolamine plasmalogens triggers synthesis of platelet-activating factor via a transacylation reaction. J. Biol. Chem., 1991, 266, 18699-18706.
59. Schiller, J.; Fuchs, B.; Arnhold, J.; Arnold, K. Contribution of reactive oxygen species to cartilage degradation in rheumatic diseases: molecular pathways, diagnosis and potential therapeutic strategies. Curr. Med. Chem., 2003, 10, 2123-2145.
60. Mitchell, T.W., Buffenstein, R.; Hulbert, A.J. Membrane phospholipid composition may contribute to exceptional longevity of the naked mole-rat (Heterocephalus glaber): A comparative study using shotgun lipidomics. Exp. Gerontol., 2007, 42, 1053-1062
61. Skaff, O.; Pattison, D.I.; Davies, M.J. The vinyl ether linkages of plasmalogens are favored targets for myeloperoxidase-derived oxidants: A kinetic study. Biochemistry, 2008, 47, 8237-8245
62. Jira, W.; Spiteller, G. Plasmalogens and their oxidative degradation products in low and high density lipoprotein. Chem. Phys. Lipids, 1996, 79, 95-100.
63. Jürgens, G.; Fell, A.; Ledinski, G.; Chen, Q.; Paultauf, F. Delay of copper-catalyzed oxidation of low density lipoprotein by in vitro enrichment with choline or ethanolamine plasmalogens. Chem. Phys. Lipids, 1995, 77, 25-31.
64. Hossain, M.S.; Hashimoto, M.; Masumura, S. Influence of docosahexaenoic acid on cerebral lipid peroxide level in aged rats with and without hypercholesterolemia. Neurosci. Lett., 1998, 244, 157-160.
65. Leray, C.; Cazenave, J.-P.; Gachet, C. Platelet phospholipids are differentially protected against oxidative degradation by plasmalogens. Lipids, 2002, 37, 285-290.
66. Jansen, G.A.; Wanders, R.J. Plasmalogens and oxidative stress: Evidence against a major role of plasmalogens in protection against superoxide anion radical. J. Inherit. Metab. Dis., 1997, 20, 85-94.
67. Kuczynski, B.; Reo, N.V. Evidence that plasmalogen is protective against oxidative stress in the rat brain. Neurochem. Res., 2006, 31, 639-656.
68. Bacot, S.; Bernoud-Hubac, N.; Baddas, N.; Chantergrel, B.; Deshayes, C.; Dotheau, A.; Lagarade, M.; Guichardant, M. Covalent binding of hydroxy-alkenals 4-HDDE, 4-HHE, and 4-HNE to ethanolamine phospholipid subclasses. J. Lipid Res., 2003, 44, 917-926.
69. Berliner, J.A.; Heinecke, J.W. The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med., 1996, 20, 707-727.
70. Witztum, J.L.; Steinberg, D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest., 1991, 88, 1785-1792.
71. Athar, M. Oxidative stress and experimental carcinogenesis. Indian J. Exp. Biol., 2002, 40, 656-667.
72. Montine, T.J., Neely, M.D.; Quin,n J.F.; Beal, M.F.; Markesbery, W.R.; Roberts, L.J. II; Morrow, J.D. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic. Biol. Med., 2002, 33, 620-626.
73. Maeba, R.; Maeda, T.; Kinoshita, M.; Takao, K.; Takenaka, H.; Kusano, J.; Yoshimura, N.; Takeoka, Y.; Yasuda, D.; Okazaki, T.; Teramoto, T. Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging. J. Atheroscler. Thromb., 2007, 14, 12-18.
74. Smith, R.E.; Lespi, P.; Di Luca, M.; Bustos, C.; Marra, F.A.; de Alaniz, M.J.; Marra, C.A. A reliable biomarker derived from plasmalogens to evaluate malignancy and metastatic capacity of human cancers. Lipids, 2008, 43, 79-89.
75. Brosche, T.; Platt, D.; Knopf, W. Decreased concentrations of serum phospholipid plasmalogens indicate oxidative burden of uraemic patients undergoing haemolysis. Nephron, 2002, 90, 58-63
76. Ross, E.A.; Koo, L.C.; Moberly, J.B. Low whole blood and erythrocyte levels of gluthatione in hemodialysis and peritoneal dialysis patients. Am. J. Kidney Dis., 1997, 30, 489-494.
77. Ha, T.K.K.; Sattar, N.; Talwar, D.; Cooney, J.; Simpson, K.; O'Reilly, D.S.J.; Lean, M.E.J. Abnormal antioxidant vitamin and carotenoid status in chronic renal failure. QJM, 1996, 89, 765-769
78. Rock, C.L.; Jahnke, M.G.; Gorenflo, D.W.; Swartz, R.D.; Messana, J.M. Racial group differences in plasma concentrations of antioxidant vitamins and carotenoids in hemodialysis patients. Am. J. Clin. Nutr., 1997, 65, 844-850.
79. Paul, J.L.; Sall, N.D.; Soni, T.; Poignet, J.L.; Lindenbaum, A.; Man, N.K. Moatti, N., Raichvarg, D. Lipid peroxidation abnormalities in hemodialyzed patients. Nephron, 1993, 64, 106-109
80. Hahnel, D.; Thiery, J.; Brosche, T.; Engelmann, B. Role of plasmalogens in the enhanced resistance of LDL to copper-induced oxidation after LDL apheresis. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 2431-2438.
81. Schlondorff, D. Cellular mechanisms of lipid injury in the glomerulus. Am. J. Kidney Dis., 1993, 22, 72-82.
82. Maggi, E.; Bellazzi, R.; Gazo, A.; Seccia, M.; Bellomo, G. Auto-antibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int., 1994, 46, 869-876.
83. Biasioli, S.; Schiavon, R.; Petrosino, L.; Cavallini, L.; Zambello, A.; De Fanti, E.; Giavarina, D. Free radicals and oxidative stress challenge dialysis patients: Effects of two different membranes. ASAIO J., 1997, 43, M766-M772.
84. Canaud, B.; Cristol, J.; Morena, M.; Leray-Moragues, H.; Bosc, J.; Vaussenat, F. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif., 1999, 17, 99-106.
85. Vamvakas, S.; Bahner, U.; Heidland, A. Cancer in end-stage renal disease: Potential factors involved -editorial-. Am. J. Nephrol., 1998, 18, 89-95.
86. Ford, A.; Hazen, S.L. Saffitz, J.E.; Gross, R.W. The rapid and reversible activation of a calcium-independent plasmalogen-selective phospholipase A2 during myocardial ischemia. J. Clin. Invest., 1991, 88, 331-335.
87. Gross, R.W. High plasmalogen and arachidonic acid content of canine myocardial sarcolemma: A fast atom bombardement mass spectroscopic and gas chromatography-mass spectroscopic characterization. Biochemistry, 1984, 23, 158-165.
88. Dudda, A.; Spiteller, G.; Kobelt, F. Lipid oxidation products in ischemic porcine heart tissue. Chem. Phys. Lipids, 1996, 82, 39-51.
89. Mizukami, M.; Aono, J.; Sakai, K.; Hata, S.; Nakano, M. Experimental myocardial infarction: Effects of a lipid peroxide, 13-hydroperoxy linoleic acid on coronary circulation in rats. Arzneimittelforschung, 1984, 34, 569-571.
90. Steinbrecher, U.P.; Parthasarathy, S.; Leake, D.S.; Witztum, J.L.; Steinberg, D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA, 1984, 81, 3883-3887.
91. Morel, D.W.; DiCorleto, P.E.; Chisolm, G.M. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis, 1984, 4, 357-364.
92. Heinle, H.; Gugeler, N.; Felde, R.; Okech, D.; Spiteller, G. Oxidation of plasmalogens produces highly effective modulators of macrophage function. Z Naturforsch., 2000, 55C, 115-120.
93. Esterbauer, H.; Ramos, P. Chemistry and pathophysiology of oxidation of LDL. Rev. Physiol. Biochem. Pharmacol., 1996, 127, 31-64.
94. Regnström, J.; Nilsson, J.; Tornvall, P.; Landou, C.; Hamsten, A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet, 1992, 339, 1183-1186.
95. Thukkani, A.K.; Hsu, F.F.; Crowley, J.R.; Wysolmerski, R.B.; Albert, C.A.; Ford, D.A. Reactive chlorinating species produced during neutrophil activation target tissue plasmalogens: Production of the chemoattractant, 2-chlorohexadecanal. J. Biol. Chem., 2002, 277, 3842-3849.
96. Malle, E.; Marsche, G.; Arnhold, J.; Davies, M.J. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim. Biophys. Acta, 2006, 1761, 392-415.
97. Thukkani, A.K., Albert, C.J.; Wildsmith, K.R.; Messner, M.C.; Martinson, B.D.; Hsu, F.F.; Ford, D.A. Myeloperoxidase-derived reactive chlorinating species from human monocytes target plasmalogens in low density lipoprotein. J. Biol. Chem., 2003, 278, 36365-36372.
98. Messner, M.C.; Albert, C.J.; McHowat, J.; Ford, D.A. Identification of lysophosphatidylcholine-chlorohydrin in human atherosclerotic lesions. Lipids, 2008, 43, 243-249.
99. Thukkani, A.K.; Martinson, B.D.; Albert, C.J.; Vogler, G.A.; Ford, D.A. Neutrophil-mediated accumulation of 2-ClHDA during myoardial infarction: 2-ClHDA-mediated myocardial injury. Am. J. Physiol. Heart Circ. Physiol., 2005, 288, H2955-H29965.
100. Marsche, G.; Heller, R.; Fauler, G.; Kovacevic, A.; Nuszkowski, A.; Graier, W.; Sattler, W.; Malle, E. 2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 2302-2306.
101. Sessa, W.C.; Garcia-Cardena, G.; Liu, J.; Keh, A.; Pollock, J.S.; Bradley, J.; Thiru, S.; Braverman, I.M.; Desai, K.M. The golgi association of endothelial nitric oxide synthase is necessary for the efficient synthesis of nitric oxide. J. Biol. Chem., 1995, 270, 17641-17644.
102. Shaul, P.W. Regulation of endothelial nitric oxide synthase: Location, location, location. Annu. Rev. Physiol., 2002, 64, 749-774.
103. Deanfield, J.E.; Halcox, J.P.; Rabelink, T.J. Endothelial function and dysfunction: Testing and clinical relevance. Circulation, 2007, 115, 1285-1295.
104. Engelmann, B.; Streich, S.; Schönthier, U.M.; Richter, W.O.; Duhm, J. Changes of membrane phospholipid composition in human erythrocytes in hyperlipidemias. I. Increased phosphatidylcholine and reduced sphingomyelin in patients with elevated levels of triacylglycerol-rich lipoproteins. Biochim. Biophys. Acta, 1992, 1165, 32-37.
105. Brosche, T.; Kral, C.; Summa, J.D.; Platt, D. Effective lovastatin therapy in elderly hypercholesterolemic patients - an antioxidative impact? Arch. Gerontol. Geriatr., 1996, 22, 207-221.
106. Kleinveld, H.A.; Demacker, P.N.M.; De Haan, A.F.J.; Stalenhoef, A.F.H. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur. J. Clin. Invest., 1993, 23, 289-295.
107. Mandel, H.; Sharf, R.; Berant, M.; Wanders, R.J.; Vreken, P.; Aviram, M. Plasmalogen phospholipids are involved in HDL-mediated cholesterol efflux: Insights from investigations with plasmalogen-deficient cells. Biochem. Biophys. Res. Commun., 1998, 250, 369-373.
108. Demediuk, P.; Saunders, R.D.; Anderson, D.K.; Means, E.D.; Horrocks, L.A. Membrane lipid changes in laminectomized and traumatized cat spinal cord. Proc. Natl. Acad. Sci. USA, 1985, 82, 7071-7075.
109. Goodenowe, D.B.; Cook, L.L.; Liu, J.; Lu, Y.; Jayasinghe, D.A.; Ahiahonu, P.W.K.; Heath, D.; Yamazaki, Y.; Flax, J.; Krenitzky, K.F.; Sparks, D.L.; Lerner, A.; Friedland, R.P.; Kudo, T.; Kamino, K.; Morihara, T.; Takeda, M.; Wood, P.L. Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer's disease and dementia. J. Lipid Res., 2007, 48, 2485-2498.
110. Wolfson, C.; Wolfson, D.B.; Asgharian, M.; M'Lan, C.E.; Ostbye, T.; Rockwood, K.; Hogan, D.B. N. Engl. J. Med., 2001, 344, 1111-1116.
111. Wanders, R.J. Peroxisomal disorders: Clinical, biochemical, and molecular aspects. Neurochem. Res., 1999, 24, 565-580.
112. Moreira, P.I.; Honda, K.; Liu, Q, Santos, M.S.; Oliveira, C.R.; Aliev, G.; Nunomura, A.; Zhu, X.; Smith, M.A.; Perry, G. Oxidative stress: The old enemy in Alzheimer's pathophysiology. Curr. Alzheimer Res., 2005, 2, 403-408.
113. Reddy, P.H. Amyloid precursor protein-mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer's disease. J. Neurochem., 2006, 96, 1-13.
114. Nunomura, A.; Perry, G.; Pappolla, M.A.; Friedland, R.P.; Hirai, K.; Chiba, S.; Smith, M.A. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J. Neuropathol. Exp. Neurol., 2000, 59, 1011-1017.
115. Ginsberg, L.; Rafique, S.; Xuereb, J.H.; Rapoport, S.I.; Gershfeld, N.L. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res., 1995, 698, 223-226.
116. Farooqui, A.A.; Rapoport, S.I.; Horrocks, L.A. Membrane phospholipid alterations in Alzheimer's disease: Deficiency of ethanolamine plasmalogens. Neurochem. Res., 1997, 22, 523-527
117. Grimm, M.O.; Grimm, H.S.; Pátzold, A.J.; Zinser, E.G., Halonen, R.; Duering, M.; Tschape, J.A.; De Strooper, B.; Müller, U.; Shen, J.; Hartmann, T. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenillin. Nat. Cell Biol., 2005, 7, 1118-1123.
118. Puglielli, L.; Tanzi, R.E.; Kovacs, D.M. Alzheimer's disease: The cholesterol connection. Nat. Neurosci., 2003, 6. 345-351.
119. Kivipelto, M.; Helkala, E.L.; Laakso, M.P.; Hänninen, T.; Hallikainen, M.; Alhainen, K.; Soininen, H.; Tuomilehto, J.; Nissinen, A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ, 2001, 322, 1447-1451.
120. Hartmann, T.; Kuchenbecker, J.; Grimm, M.O.W. Alzheimer's disease: The lipid connection. J. Neurochem., 2007, 103 (Suppl.1), 159-170.
121. Cutler, R.G.; Kelly, J.; Storie, K.; Pedersen, W.A.; Tammara, A.; Hatanpaa, K.; Troncoso, J.C.; Mattson, M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2004, 101, 2070-2075.
122. Wood, W.G.; Schroeder, F. Igbavboa, U.; Avdulov, N.A.; Chochina, S.V. Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol. Aging, 2002, 23, 685-694.
123. Fassbender, K.; Simons, M.; Bergmann, C.; Stroick, M.; Lutjohann, D.; Keller, P.; Runz, H.; Kuhl, S.; Bertsch, T.; von Bergmann, K.; Hennerici, M.; Beyreuther, K.; Hartmann, T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 2001, 98, 5856-5861.
124. Simons, M.; Keller, P.; De Strooper, B.; Beyreuther, K.; Dotti, C.G.; Simons, K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA, 1998, 95, 6460-6464.
125. Wahrle, S. Das, P.; Nyborg, A.C.; McLendon, C.; Shoji, M.; Kawarabayashi, T.; Younkin, L.H.; Younkin, S.G.; Golde, T.E. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis., 2002, 9, 11-23.
126. Zha, Q.; Ruan, Y.; Hartmann, T.; Beyreuther, K.; Zhang, D. GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol. Psychiatry, 2004, 9, 946-952.
127. Avdulov, N.A.; Chochina, S.V.; Igbavboa, U.; Warden, C.S.; Vassiliev, A.V.; Wood, W.G. Lipid binding to amyloid beta-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem., 1997, 69, 1746-1752.
128. Markesberry, W.R.; Carney, J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol., 1999, 9, 133-146.
129. Farooqui, A.A.; Ong, W.Y.; Horrocks, L.A. Plasmalogens, docosa-hexaenoic acid and neurological disorders. Adv. Exp. Med. Biol., 2003, 544, 335-354.
130. Mulder, C.; Wahlund, L.O.; Teerlink, T.; Blomberg, M.; Veerhuis, R.; van Kamp, G.J.; Scheltens, P.; Scheffer, P.G. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J. Neural. Transm., 2003, 110, 949-955.
131. Pettegrew, J.W.; Klunk, W.E.; Kanal, E.; Panchalingam, K.; McClure, R.J. Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol. Aging, 1995, 16, 973-975.
132. Selley, M.L.; Close, D.R.; Stern, S.E. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol. Aging, 2002, 23, 383-388.
133. Iwamoto, N.; Kobayashi, K.; Kosaka, K. The formation of prostaglandins in the postmortem cerebral cortex of Alzheimer-type dementia patients. J. Neurol., 1989, 236, 80-84.
134. Palmer, A.M.; Burns, M.A. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res., 1994, 645, 338-342.
135. Farooqui, A.A.; Horrocks, L.A. Excitotoxicity and neurological disorders: Involvement of membrane phospholipids. Int. Rev. Neurobiol., 1994, 36, 267-323.
136. Ginsberg, L.; Xuereb, J.H.; Gershfeld, N.L. Membrane instability, plasmalogen content, and Alzheimer's disease. J. Neurochem., 1998, 70, 2533-2538.
137. Perichon, R.; Moser, A.B.; Wallace, W.C.; Cunnigham, S.C.; Roth, G.S.; Moser, H.W. Peroxisomal disease cell lines with cellular plasmalogen deficiency have impaired muscarinic cholinergic signal transduction activity and amyloid precursor protein secretion. Biochem. Biophys. Res. Commun., 1998, 248, 57-61.
138. Guan, Z.; Wang, Y.; Cairns, N.J.; Lantos, P.L.; Dallner, G.; Sindelar, P.J. Decrease and structural modifications of phosphatidyletha-nolamine plasmalogen in the brain with Alzheimer disease. J. Neuropathol. Exp. Neurol., 1999, 58, 740-747.
139. Lim, G.P.; Calon, F.; Morihara, T.; Yang, F.; Teter, B.; Ubeda, O.; Salem, N. Jr.; Frautschy, S.A., Cole, G.M. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci., 2005, 25, 3032-3040.
140. Lohner, K.; Balgavy, P.; Hermetter, A.; Paltauf, F.; Laggner, P. Stabilization of non-bilayer structures by the etherlipid ethanolamine plasmalogen. Biochim. Biophys. Acta, 1991, 1061, 132-140.
141. Urano, S.; Asai, Y.; Makabe, S.; Matsuo, M.; Izumiyama, N.; Ohtsubo, K.; Endo, T. Oxidative injury of synapse and alteration of antioxidative defense systems in rats, and its prevention by vitamin E. Eur. J. Biochem., 1997, 245, 64-70.
142. Söderberg, M.; Edlund, C.; Kristensson, K.; Dallner, G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids, 1991, 26, 421-425.
143. Zommara, M.; Tachibana, N.; Mitsui, K.; Nakatani, N.; Sakono, M.; Ikeda, I.; Imaizumi, K. Inhibitory effect of ethanolamine plasmalogen on iron- and copper-dependent lipid peroxidation. Free Radic. Biol. Med., 1995, 18, 599-602.
144. Sindelar, P.J.; Guan, Z.Z.; Dallner, G.; Ernster, L. The protective role of plasmalogens in iron-induced lipid peroxidation. Free Radic. Biol. Med., 1999, 26, 318-324.
145. Calzada, C.; Bruckdorfer, K.R.; Rice-Evans, C.A. The influence of antioxidant nutrients on platelet function in healthy volunteers. Atherosclerosis, 1997, 128, 97-105.
146. Hahnel, D.; Beyer, K.; Engelmann, B. Inhibition of peroxyl radical-mediated lipid oxidation by plasmalogen phospholipids and alphatocopherol. Free Radic. Biol. Med., 1999, 27, 1087-1094.
147. Albers, D.S.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural. Trans. Suppl., 2000, 59, 133-154.
148. Bassett, C.N.; Montine, T.J. Lipoproteins and lipid peroxidation in Alzheimer's disease. J. Nutr. Health Aging, 2003, 7, 24-29.
149. Reddy, T.S.; Horrocks, L.A. Effects of neonatal undernutrition on the lipid composition of gray matter and white matter in rat brain. J. Neurochem., 1982, 38, 601-605.
150. Reddy, T.S.; Rajalakshmi, R.; Ramakrishnan, C.V. Effects of nutritional rehabilitation on the content and lipid composition of brain gray and white matter of neonatally undernourished rats. J. Neurochem., 1982, 39, 1297-1301.
151. Yanagihara, T.; Cumings, J.N. Alterations of phospholipids, particularly plasmalogens, in the demyelination of multiple sclerosis as compared with that of cerebral oedema. Brain, 1969, 92, 59-70.
152. Nixon, R.A. Niemann-Pick Type C disease and Alzheimer's disease: The APP-endosome connection fattens up. Am. J. Pathol., 2004, 164, 757-761.
153. Thai, T.P.; Rodemer, C.; Jauch, A.; Hunziker, A.; Moser, A.; Gorgas, K.; Just, W.W. Impaired membrane traffic in defective ether lipid biosynthesis. Hum. Mol. Genet., 2001, 10, 127-136
154. Schedin, S.; Sindelar, P.J.; Pentchev, P.; Brunk, U.; Dallner, G. Peroxisomal impairment in Niemann-Pick type C disease. J. Biol. Chem., 1997, 272, 6245-6251.
155. Heymans, H.S.A., Schutgens, R.B.H.; Tan, R.; van den Bosch, H.; Borst, P. Severe plasmalogen deficiency in tissues of infants without peroxisomes (Zellweger syndrome) Nature, 1983, 306, 69-70.
156. Datta, N.S.; Wilson, G.N.; Hajra, A.K. Deficiency of enzymes catalyzing the biosynthesis of glycerol-ether lipids in Zellweger syndrome. A new category of metabolic disease involving the absence of peroxisomes. N. Engl. J. Med., 1984, 311, 1080-1083.
157. Brosche, T. Plasmalogen phospholipids - facts and theses to their antioxidative qualities. Arch. Gerontol. Geriatr., 1997, 25, 73-81.
158. Harman, D. Aging: A theory based on free radical and radiation chemistry. J. Gerontol., 1956, 11, 298-300.
159. Rouser, G.; Yamamoto, A. Curvilinear regression course of human brain lipid composition changes with age. Lipids, 1968, 3, 284-287.
160. Weisser, M.; Vieth, M.; Stolte, M.; Riederer, P.; Pfeuffer, R.; Leblhuber, F.; Spiteller, G. Dramatic increase of alpha-hydroxy-aldehydes derived from plasmalogens in the aged human brain. Chem. Phys. Lipids, 1997, 90, 135-142.
161. Weisser, M.; Spiteller, G. Increase of aldehydic compounds derived from plasmalogens in the brain of aged cattle. Chem. Phys. Lipids,
162. Roberts, L.D.; McCombie, G.; Titman, C.M.; Griffin, J.L. A matter of fat: An introduction to lipidomic profiling methods. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 871, 174-181.
163. Folch, J.; Lees, M.; Sloane Stanley, G.H.S. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem., 1957, 226, 497-509.
164. Olsson, N.U.; Salem, N. Molecular species analysis of phospholipids. J. Chromatogr. B, 1997, 692, 245-256.
165. Christie, W.W. Lipid Analysis, The Oily Press: Bridgwater, England, 2003.
166. Clejan, S. HPLC analytical methods for the separation of molecular species of fatty acids in diacylglycerol and cellular phospholipids. Methods Mol Biol., 1998, 105, 255-274.
167. Patton, G.M., Robins, S.J. Separation and quantitation of phospholipid classes by HPLC. Methods Mol. Biol., 1998, 110, 193-215.
168. McCluer, R.H., Ullmann, M.D., Jungalwala, F.B. HPLC of glycosphingolipids and phospholipids. Adv. Chromatogr., 1986, 25, 309-353.
169. Touchstone, J.C. Thinlayer chromatographic procedures for lipid separation. J. Chromatogr. B, 1995, 671, 169-195.
170. Saito, M.; Horikawa, M.; Iwamori, Y.; Sakakihara, Y.; Mizuguchi, M.; Igarashi, T.; Fujiki, Y.; Iwamori, M. Alterations in the molecular species of plasmalogen phospholipids and glycolipids due to peroximal dysfunction in Chinese hamster ovary-mutant Z65 cells by FAB MS method. J. Chromatogr. B, 2007, 852, 367-373.
171. Fuchs, B.; Arnold, K.; Schiller, J. In Encyclopedia of Analytical Chemistry; Robert A. Meyers, Ed.; John Wiley & Sons: Chichester, 2008; pp. 1-36.
172. Luftmann, H.; Aranda, M.; Morlock, G.E. Automated interface for hyphenation of planar chromatography with mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21, 3772-3776.
173. Wilson, S.R.; Czarnik, A.W. Combinatorial Chemistry - Synthesis and Applications, Wiley: New York, 1997.
174. DeLong, C.J.; Baker, P.R.S.; Samuel, M.; Cui, Z.; Thomas, M.J. Molecular species composition of rat liver phospholipids by ESIMS/MS: The effect of chromatography. J. Lipid Res. 2001, 42, 1959-1968.
175. Fuchs, B.; Schiller, J.; Süß, R.; Zscharnack, M.; Bader, A.; Müller, P.; Schürenberg, M.; Becker, M.; Suckau, D. Analysis of stem cell lipids by offline HPTLC-MALDI-TOF MS. Anal. Bioanal. Chem., 2008, 392, 849-860.
176. Murphy, R.C. Mass Spectrometry of Phospholipids: Tables of Molecular and Product Ions, Illuminati Press: Denver, 2002.
177. Kuksis, A. Quantitative and positional analysis of fatty acids. Lab. Res. Methods Biol. Med. 1984, 10, 77-131.
178. Gottwald, W. GC für Anwender, Wiley-VCH: Weinheim, 1995.
179. Chapman, J.R. In Encyclopedia of Analytical Science; Alan Townsend, Ed.; Academic Press: London, 1995; Vol. 5.
180. Chapman, J.R. Practical Organic Mass Spectrometry - A Guide for Chemical and Biochemical Analysis, John Wiley & Sons: Chichester, 1993.
181. Rütters, H.; Sass, H.; Cypionka, H.; Rullkötter, J. Phospholipid analysis as a tool to study complex microbial communities in marine sediments. J. Microbiol. Methods, 2002, 48, 149-160.
182. Lorenz, S.A.; Maziarz, E.P.; Wood, T.D. Electrospray ionization Fourier transform mass spectrometry of macromolecules: The first decade. Appl. Spectrosc., 1999, 53, 18A-36A.
183. Seifert, W.E.; Caprioli, R.M. Fast atom bombardment mass spectrometry. Methods Enzymol., 1996, 270, 453-486.
184. Schiller, J; Arnhold, J.; Benard, S.; Müller, M.; Reichl, S.; Arnold, K. Lipid analysis by matrix-assisted laser-desorption and ionization mass spectrometry: A methodological approach. Anal. Biochem., 1999, 267, 46-56.
185. Zenobi, R.; Knochenmuss, R. Ion formation in MALDI mass spectrometry. Mass Spectrom. Rev., 1999, 17, 337-366.
186. Postle, A.D.; Wilton, D.C.; Hunt, A.N.; Attard, G.S. Probing phospholipid dynamics by electrospray ionisation mass spectrometry. Prog. Lipid Res., 2007, 46, 200-224.
187. Hsu, F.-F.; Turk, J. Differentiation of 1-O-alk-1'-enyl-2-acyl and 1-O-alkyl-2-acyl glycerophospholipids by multiple-stage linear iron-trap mass spectrometry with electrospray ionization. J. Am. Soc. Mass Spectrom., 2007, 18, 2065-2073.
188. Zemski Berry, K.A.; Murphy, R.C. Electrospray ionization tandem mass spectrometry of glycerophosphoethanolamine plasmalogen phospholipids. J. Am. Soc. Mass Spectrom., 2004, 15, 1499-1508.
189. Gao, F.; Tian, X.; Wen, D.; Liao, J.; Wang, T.; Liu, H. Analysis of phospholipid species in rat peritoneal surface layer by liquid chromatography electrospray ionization ion-trap mass spectrometry. Biochim. Biophys. Acta, 2006, 1761, 667-676.
190. Johnson, D.W. A modified Girard derivatizing reagent for universal profiling and trace analysis of aldehydes and ketones by electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom., 2007, 21, 2926-2932.
191. Al-Saad, K.A.; Zabrouskov, V.; Siems, W.F.; Knowles, N.R.; Hannan, R.M.; Hill, H.H. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of lipids: Ionization and prompt fragmentation patterns. Rapid Commun. Mass Spectrom., 2003, 17, 87-96.
192. Fuchs, B.; Schober, C.; Richter, G.; Süß, R.; Schiller, J. MALDITOF MS of phosphatidylethanolamines: Different adducts cause different post source decay (PSD) fragment ion spectra. J. Biochem. Biophys. Methods, 2007, 70, 689-692.
193. Schiller, J.; Süß, R.; Petković, M.; Hilbert, N.; Müller, M.; Zschörnig, O.; Arnhold, J.; Arnold, K. CsCl as an auxiliary reagent for the analysis of phosphatidylcholine mixtures by matrix-assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI-TOF MS). Chem. Phys. Lipids, 2001, 113, 123-131.
194. Estrada, R.; Yappert, Y.C. Regional phospholipid analysis of porcine lens membranes by matrixx-assisted laser desorption/ionization time-of-flight mass spectrometry. J. Mass Spectrom., 2004, 39, 1531-1540.
195. Fuchs, B.; Schiller, J.; Cross, M.A. Apoptosis-associated changes in the glycerophospholipid composition of hematopoietic progenitor cells monitored by 31P NMR spectroscopy and MALDI-TOF mass spectrometry. Chem. Phys. Lipids, 2007, 150, 229-238.
196. Müller, M.; Schiller, J.; Petković, M.; Oehrl, W.; Heinze, R.; Wetzker, R.; Arnold, K.; Arnhold, J. Limits for the detection of (poly-) phosphoinositides by matrix-assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI-TOF MS). Chem. Phys. Lipids, 2001, 110, 151-164.
197. Gellermann, G.P.; Appel, T.R.; Davies, P.; Diekmann, S. Paired helical filaments contain small amounts of cholesterol, phosphatidylcholine and sphingolipids. Biol. Chem., 2006, 387, 1267-1274
198. Estrada, R.; Yappert, M.C. Alternative approaches for the detection of various phospholipid classes by matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. J. Mass Spectrom., 2004, 39, 412-422.
199. Schiller, J.; Arnhold, J.; Glander, H.-J.; Arnold, K. Lipid analysis of human spermatozoa and seminal plasma by MALDI-TOF mass spectrometry and NMR spectroscopy - effects of freezing and thawing. Chem. Phys. Lipids, 2000, 106, 145-156.
200. 31P NMR. Eur. J. Biochem. 1997, 243, 328-335.
201. Jones, J.J.; Borgmann, S.; Wilkins, C.L.; O'Brien, R.M. Characterizing the phospholipid profiles in mammalian tissues by MALDI FTMS. Anal. Chem., 2006, 78, 3062-3071.
202. Jones, J.J.; Stump, M.J.; Fleming, R.C.; Lay, J.O.; Wilkins, C.L. Investigation of MALDI-TOF and FT-MS techniques for analysis of Escherichia coli whole cells. Anal. Chem., 2003, 75, 1340-1347.
203. Cornett, D.S.; Reyzer, M.L.; Chaurand, P.; Caprioli, R.M. MALDI imaging mass spectrometry: Molecular snapshots of biochemical systems. Nat. Methods, 2007, 4, 828-833.
204. Garrett, T.J.; Yost, R.A. Analysis of intact tissue by intermediate-pressure MALDI on a linear ion trap mass spectrometer. Anal. Chem., 2006, 78, 2465-2469.
205. Cha, S.; Yeung, E.S. Colloidal graphite-assisted laser desorption/ ionization mass spectrometry and MSn of small molecules. 1.Imaging of cerebrosides directly from rat brain tissue. Anal. Chem., 2007, 79, 2373-2385.
206. Jackson, S.N.; Wang, H.-Y.J.; Woods, A.S.; Ugarov, M.; Egan, T.; Schultz, J.A. Direct tissue analysis of phospholipids in rat brain using MALDI-TOF MS and MALDI-ion mobility-TOF MS. J. Am. Soc. Mass Spectrom., 2005, 16, 133-138.
207. Han, X.; Gross, R.W. Shotgun lipidomics: Electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev., 2005, 24, 367-412.
208. Gross, R.W.; Jenkins, C.M.; Yang, J.; Mancuso, D.J.; Han, X. Functional lipidomics: The roles of specialized lipids and lipid-protein interaction is modulating neuronal function. Prostaglandins Other Lipid Mediat., 2005, 77, 52-64.
209. Ishida, M.; Yamazaki, T.; Houjou, T.; Imagawa, M.; Harada, A.; Inoue, K.; Taguchi, R. High-resolution analysis by nano-electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry for the identification of molecular species of phospholipids and their oxidized metabolites. Rapid Commun. Mass Spectrom., 2004, 18, 2486-2494.
210. 13C-NMR-Spektroskopie, Georg Thieme Verlag: Stuttgart, 1984.
211. Braun, S.; Kalinowski, H.O.; Berger, S. 150 and more basic NMR experiments, Wiley-VCH: Weinheim, 1998.
212. Campbell, I.D.; Dobson, C. M. The application of high resolution nuclear magnetic resonance to biological systems. Methods Biochem. Anal., 1979, 25, 1-133.
213. Arnhold, J.; Panasenko, O.M.; Schiller, J.; Vladimirov, Yu.A.; Arnold, K. The action of hypochlorous acid on phosphatidylcholine liposomes in dependence on the content of double bonds. Stoichiometry and NMR analysis. Chem. Phys. Lipids, 1995, 78, 55-64.
214. Alkan, A.; Kutlu, R.; Yakinci; C.; Sigirci, A.; Aslan, M.; Sarac, K. Delayed myelination in a rhizomelic chondrodysplasia punctata case: MR spectroscopy findings. Magn. Reson. Imaging, 2003, 21, 77-80.
215. Hikita, T.; Tadano-Aritomi, K.; Iida-Tanaka, N.; Anand, J.K.; Ishizuka, I.; Hakomori, S. A novel plasmal conjugate to glycerol and psychosine ("glyceroplasmalopsychosine"): Isolation and characterization from bovine brain white matter. J. Biol. Chem., 2001, 276, 23084-23091.
216. Iida-Tanaka, N.; Hikita, T.; Hakomori, S.; Ishizuka, I. Conformational studies of a novel cationic glycolipid, glyceroplasmalopsychosine, from bovine brain by NMR spectroscopy. Carbohydr. Res., 2002, 337, 1775-1779.
217. Subramanian, A.; Shankar Joshi, B.S.; Roy, A.D.; Roy, R.; Gupta, V.; Dang, R.S. NMR spectroscopic identification of cholesterol esters, plasmalogen and phenolic glycolipids as fingerprint markers of human intracranial tuberculomas. NMR Biomed., 2008, 21, 272-288.
218. 31P NMR spectroscopy. Magn. Reson. Med., 2000, 44, 215-223.
219. 31P NMR spectroscopy to the characterization of the phospholipid composition of tissues and body fluids - a methodological review. Med. Sci. Monit., 2002, 8, 205-222.
220. Fuchs, B.; Schiller, J.; Arnold, K. Sodium cholate: An ideal detergent to obtain highly resolved 31P NMR spectra of phospholipids. Chim. Oggi, 2006, Suppl. "Household & Personal Care Today", 28-31.
221. 31P NMR Spectroscopy of phospholipids: From micells to membranes. Curr. Anal. Chem., 2007, 3, 283-301
222. 31P NMR. Magn. Reson. Med., 1993, 30, 476-484.
223. Pettegrew, J.W.; Panchalingam, K.; Hamilton, R.L.; McClure, R.J. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res., 2001, 26, 771-782.
224. Pettegrew, J.W.; Panchalingam, K.; Levine, J.; McClure, R.J.; Gershon, S.; Yao, J.K. Chronic myo-inosotol increases rat brain phosphatidylethanolamine plasmalogen. Biol. Psychiatry, 2001, 49, 444-453.
225. Hoffman-Kuczynski, B.; Reo, N.V. Studies of myo-inositol and plasmalogen metabolism in rat brain. Neurochem. Res., 2004, 29, 843-855.
226. Hoffman-Kuczynski, B.; Reo, N.V. Administration of myo-inositol plus ethanolamine elevates phosphatidylethanolamine plasmalogen in the rat cerebellum. Neurochem. Res., 2005, 30, 47-60.
227. Kuczynski, B.; Reo, N.V. Evidence that plasmalogen is protective against oxidative stress in the rat brain. Neurochem. Res., 2006, 31, 639-656.
228. Spickett, C.M.; Pitt, A.R.; Brown, A.J. Direct observation of lipid hydroperoxides in phospholipid vesicles by electrospray mass spectrometry. Free Radic. Biol. Med., 1998, 25, 613-620.
229. Spickett, C.M. Chlorinated lipids and fatty acids: An emerging role in pathology. Pharmacol. Therapeut., 2007, 115, 400-409.
230. Arnhold, J.; Osipov, A.N.; Spalteholz, H.; Panasenko, O.M.; Schiller, J. Effects of hypochlorous acid on unsaturated phosphatidylcholines. Free Radic. Biol. Med., 2001, 31, 1111-1119.
231. Fuchs, B.; Müller, K.; Göritz, F.; Blottner, S.; Schiller, J. Characteristic oxidation products of choline plasmalogens are detectable in cattle and roe deer spermatozoa by MALDI-TOF mass spectrometry. Lipids, 2007, 42, 991-998.
232. Wildsmith, K.R.; Albert, C.J.; Hsu, F.-F.; Kao, J.L.-F.; Ford, D.A. Myeloperoxidase-derived 2-chlorohexadecanal forms Schiff bases with primary amines of ethanolamine glycerophospholipids and lysine. Chem. Phys. Lipids, 2006, 139, 157-170.